Pages that link to "Q7194603"
Jump to navigation
Jump to search
The following pages link to pimavanserin (Q7194603):
Displaying 50 items.
- Parkinson's disease (Q11085) (← links)
- dementia (Q83030) (← links)
- psychosis (Q170082) (← links)
- Lewy body dementia (Q1331905) (← links)
- parkinsonian syndrome (Q1531991) (← links)
- 5-hydroxytryptamine receptor 2A (Q1949517) (← links)
- Acadia Pharmaceuticals (Q4671580) (← links)
- Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist (Q28296508) (← links)
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders (Q28302151) (← links)
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day (Q34297936) (← links)
- Pimavanserin for the treatment of Parkinson's disease psychosis (Q34369646) (← links)
- Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis (Q34660675) (← links)
- Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers (Q35108041) (← links)
- Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs (Q38167630) (← links)
- On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis (Q38200546) (← links)
- Pimavanserin (Q38690238) (← links)
- Pimavanserin: First Global Approval (Q38854991) (← links)
- Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys (Q39724020) (← links)
- Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. (Q43253183) (← links)
- Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios (Q43412717) (← links)
- Pimavanserin as treatment for Parkinson's disease psychosis (Q44391451) (← links)
- Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. (Q45934868) (← links)
- Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease (Q46466164) (← links)
- Nuplazid (Q47521918) (← links)
- Pimavanserin: An Inverse Agonist Antipsychotic Drug (Q48012406) (← links)
- (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand (Q48342220) (← links)
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease (Q48895783) (← links)
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial (Q48897517) (← links)
- The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease (Q50876872) (← links)
- Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. (Q51583546) (← links)
- Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease (Q61902402) (← links)
- ACP-103 to Treat Parkinson's Disease (Q62110537) (← links)
- Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression (Q62810625) (← links)
- A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease (Q63396925) (← links)
- Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis (Q63534380) (← links)
- A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease (Q63576417) (← links)
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis (Q63830553) (← links)
- Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia (Q64172643) (← links)
- Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) (Q64173267) (← links)
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (Q64397507) (← links)
- An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients (Q64647397) (← links)
- A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis (Q64721120) (← links)
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (Q64792848) (← links)
- A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis (Q65382529) (← links)
- Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone (Q65389220) (← links)
- A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis (Q65471344) (← links)
- Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (Q66062662) (← links)
- Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (Q66062675) (← links)
- The Sub-Sero Study (Q66063458) (← links)
- Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2) (Q66065625) (← links)